NG Bio

Mesenbio is a preclinical biopharmaceutical company based at the University of York, specializing in cell-derived therapies. It has developed a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which aims to enhance the treatment pipeline by addressing significant challenges in extracellular vesicle therapy. The company focuses on creating innovative treatments, including a novel therapy for arthritis derived from engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio seeks to transform medical approaches to musculoskeletal diseases, thereby providing more effective therapeutic options.

Bastion Therapeutics is a preclinical stage biotechnology company focused on developing innovative anti-inflammatory cell therapies. Utilizing its proprietary platform technology, the company aims to enhance regulatory T cells (Tregs) within the immune system. By targeting neuroinflammation in critical areas of the central nervous system, Bastion Therapeutics seeks to protect neurons and improve synaptic connectivity, ultimately helping patients to maintain cognitive function and prevent deterioration. Through its research and development efforts, the company is positioning itself to address significant unmet medical needs in the realm of neuroinflammatory conditions.